Mok T - Search Results

1

FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer.

Yang S, Liu Y, Li MY, Ng CSH, Yang SL, Wang S, Zou C, Dong Y, Du J, Long X, Liu LZ, Wan IYP, Mok T, Underwood MJ, Chen GG. Yang S, et al. Among authors: mok t. Mol Cancer. 2017 Jul 17;16(1):124. doi: 10.1186/s12943-017-0700-1. Mol Cancer. 2017. PMID: 28716029 Free PMC article.

2

Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung.

Chan AT, Teo PM, Lam KC, Chan WY, Chow JH, Yim AP, Mok TS, Kwan WH, Leung TW, Johnson PJ. Chan AT, et al. Among authors: mok ts. Cancer. 1998 Sep 1;83(5):925-9. doi: 10.1002/(sici)1097-0142(19980901)83:5<925::aid-cncr18>3.0.co;2-x. Cancer. 1998. PMID: 9731896 Clinical Trial.

3

Lack of expression for the suppressor PML in human small cell lung carcinoma.

Zhang P, Chin W, Chow LT, Chan AS, Yim AP, Leung SF, Mok TS, Chang KS, Johnson PJ, Chan JY. Zhang P, et al. Among authors: mok ts. Int J Cancer. 2000 Mar 1;85(5):599-605. doi: 10.1002/(sici)1097-0215(20000301)85:5<599::aid-ijc1>3.0.co;2-#. Int J Cancer. 2000. PMID: 10699936 Free article.

4

A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma.

Mok TS, Zee B, Chan AT, Yeo W, Yang WT, Yim A, Leung SF, Nguyen B, Leung TW, Johnson P. Mok TS, et al. Cancer. 2000 Aug 1;89(3):543-50. Cancer. 2000. PMID: 10931453 Clinical Trial.

5

Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer.

Ng CS, Zhang J, Wan S, Lee TW, Arifi AA, Mok T, Lo DY, Yim AP. Ng CS, et al. Among authors: mok t. J Surg Oncol. 2002 Feb;79(2):101-6. doi: 10.1002/jso.10046. J Surg Oncol. 2002. PMID: 11815997

6

Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.

Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K. Mok T, et al. J Thorac Oncol. 2010 Oct;5(10):1609-15. doi: 10.1097/JTO.0b013e3181e15d55. J Thorac Oncol. 2010. PMID: 20808255 Free article. Clinical Trial.

7

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.

Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. Wu YL, et al. Among authors: mok t. BMC Cancer. 2011 Oct 7;11:430. doi: 10.1186/1471-2407-11-430. BMC Cancer. 2011. PMID: 21982342 Free PMC article. Clinical Trial.

8

Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.

Mok T, Lee K, Tang M, Leung L. Mok T, et al. Future Oncol. 2014 Apr;10(5):813-22. doi: 10.2217/fon.14.22. Future Oncol. 2014. PMID: 24799062

9

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.

Pallaud C, Reck M, Juhasz E, Szima B, Yu CJ, Burdaeva O, Orlov S, Hilton M, Archer V, Mok T. Pallaud C, et al. Among authors: mok t. Lung Cancer. 2014 Oct;86(1):67-72. doi: 10.1016/j.lungcan.2014.07.019. Epub 2014 Aug 2. Lung Cancer. 2014. PMID: 25154982 Clinical Trial.

10

Novel targeted agents for the treatment of lung cancer in China.

Liu SY, Mok T, Wu YL. Liu SY, et al. Among authors: mok t. Cancer. 2015 Sep 1;121 Suppl 17:3089-96. doi: 10.1002/cncr.29522. Cancer. 2015. PMID: 26331815 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

590 results

Search Page